Fluorothyazinone 300 mg; Fluorothyazinone 600 mg; Fluorothyazinone 3900 mg
An Open Study to Assess the Safety and Pharmacokinetics of Fluorothyazinone Used as a Single-Dose Administration or a Treatment Course in Healthy Volunteers
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT03205462/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза I — первое применение у людей. Проверяют безопасность и подбирают дозу, участников немного.
- В исследовании участвуют здоровые добровольцы.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–45 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 25 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (12.2017) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 14 · невключение: 17
Критерии включения
- \- subject is a male or female between the age of 18 - 45 years;
- subject provides written informed consent;
- subject agrees to use effective contraceptive methods during the entire period of participation in the study (one of the following methods will be used: sexual abstinence; condoms (male or female with or without spermicidal agent); diaphragm or cervical cap with spermicidal agent; intrauterine device); in cases where subjects use hormonal contraceptives, their administration should be discontinued at least 2 months prior to the study commencement date;
- body mass index (BMI) of subject: 18.5 ≤ BMI ≤ 30;
- subject has no acute communicable diseases/recurrence of chronic communicable diseases during the participation in the study and 7 days prior to start of the therapy;
- subject has no severe allergic diseases in the medical history (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, serum disease);
- in medical history and based on the screening results, subject has no diseases of the gastrointestinal system, liver, kidneys, cardiovascular system, CNS, locomotion system, urogenital and endocrine systems that could affect the assessment of the study results;
- subject has a negative result of the blood or urine pregnancy test (for females of childbearing age) not more than 24 hours prior to receiving the first dose of the studied product;
- subject has negative tests for HIV, hepatitis B and c, syphilis;
- subject has a negative result of the urine test for residual narcotic drugs;
- subject has a negative result of the breath alcohol test;
- subject has no hematopoietic malignancies;
- subject has no malignant neoplasms;
- indicators of clinical biochemical analysis, complete blood count and clinical urine test at a screening visit are within the normal range of reference values*
Критерии невключения
- \- subject has participated in another clinical trial over the last 90 days;
- subject has experienced symptoms of respiratory disease for the last 3 days;
- subject has received treatment with steroids for the last 10 days (except products for intranasal and topical application);
- subject has received immunoglobulins or other blood products over the last 3 months;
- subject has received immunosuppressive and/or immunomodulating agents within 6 months prior to the start of the study;
- subject has taken medications that have considerable effects on hemodynamics, liver function, etc. (barbiturates, omeprosole, cimetidine, etc.) within less than 30 days prior to the start of the study;
- regular previous or current use of narcotic drugs by subject;
- pregnancy or breast feeding;
- GI system surgeries in subject's history within a one-year period before the subject enters the study;
- subject has systolic blood pressure less than 100 mm Hg or greater than 139 mm Hg; diastolic blood pressure less than 60 mm Hg or greater than 90 mm Hg; heart rate lower than 60 beats per minute or above 90 beats per minute;
- subject has exacerbation of allergic diseases or history of anaphylactic reactions or angioneurotic edema;
- allergic reactions to components of the studied product and concurrent antibacterial agent;
- subject has a concomitant disease which may affect the assessment of the study results: active TB form; chronic hepatic and renal diseases; considerable impairment of thyroid function and other endocrine diseases (diabetes mellitus), severe diseases of the hematopoietic system; epilepsy and other CNS disorders; myocardial infarction in previous history; myocarditis; endocarditis; ischemic heart disease; autoimmune disorders; severe chronic diseases requiring follow-up at the hospital; and, other diseases that, in opinion of the Investigator, will not allow a subject to take part in the study or may affect the study course and/or its results (e.g. assessment of the safety parameters);
- blood donation (at least 450 ml of blood or plasma) by subject in less than 2 months prior to the start of the study;
- subject has a history of the consumption of more than 5 units (0.25 l of pure alcohol) a week
- subject smokes more than 10 cigarettes a day;
- scheduled hospitalization and/or surgery during the period of participation in the study.
Источник: ClinicalTrials.gov, NCT03205462 · запись обновлена в реестре 24 июля 2018.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 8
- Product safety evaluation by assessing its impact on the vital signs (systolic and diastolic blood pressure, heart rate, body temperature) and clinical laboratory test results in healthy volunteers after administration of the product — through study completion, an average of 3 month
Цель исследования
The current Phase I clinical trial has been developed to assess the safety and tolerability of the Fluorothyazinone drug used as a single-dose administration and a treatment course in healthy volunteers. This dose-escalation trial will be conducted with sequential enrollment of volunteers.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT03205462 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.